Everolimus + Everolimus Placebo
Phase 3Completed 2 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Neuroendocrine Tumors of Pancreatic Origin
Conditions
Advanced Neuroendocrine Tumors of Pancreatic Origin
Trial Timeline
Jul 1, 2007 → Mar 1, 2014
NCT ID
NCT00510068About Everolimus + Everolimus Placebo
Everolimus + Everolimus Placebo is a phase 3 stage product being developed by Novartis for Advanced Neuroendocrine Tumors of Pancreatic Origin. The current trial status is completed. This product is registered under clinical trial identifier NCT00510068. Target conditions include Advanced Neuroendocrine Tumors of Pancreatic Origin.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Neuroendocrine Tumors of Pancreatic Origin were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01379521 | Phase 2 | Terminated |
| NCT01035229 | Phase 3 | Completed |
| NCT00790036 | Phase 3 | Completed |
| NCT00510068 | Phase 3 | Completed |
Competing Products
20 competing products in Advanced Neuroendocrine Tumors of Pancreatic Origin